RSTP-1000
Demoralization syndrome in patients with cancer
Pre-clinicalActive
Key Facts
Indication
Demoralization syndrome in patients with cancer
Phase
Pre-clinical
Status
Active
Company
About Reset Pharmaceuticals
Reset Pharmaceuticals is a private, pre-clinical stage biotech targeting the urgent and underserved mental health condition of demoralization syndrome in oncology patients. Its lead asset, RSTP-1000, is a proprietary psilocybin-inspired therapy in development, leveraging a worldwide license from NYU based on the seminal work of Dr. Stephen Ross. The company is positioning itself in a high-value oncology supportive care market with no approved treatments, aiming to offer a rapid and durable therapeutic alternative to ineffective antidepressants.
View full company profile